Synlogic Inc SYBX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if SYBX is a good fit for your portfolio.
News
-
Synlogic Reports Fourth Quarter and Full Year 2023 Financial Results
-
Synlogic Adopts Limited Duration Stockholders Rights Plan
-
Synlogic Announces Decision to Discontinue Synpheny-3 Study and Provides Corporate Update
-
Synlogic Announces Publication of Preclinical and Clinical Data for SYNB1353 as a Potential Treatment for Classical Homocystinuria
-
Synlogic Shares Rise 10% on FDA Fast Track Designation of PKU Drug
Trading Information
- Previous Close Price
- $1.87
- Day Range
- $1.79–1.94
- 52-Week Range
- $1.55–10.20
- Bid/Ask
- $1.78 / $1.87
- Market Cap
- $21.43 Mil
- Volume/Avg
- 21,787 / 149,578
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 3.47
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 6
- Website
- https://www.synlogictx.com
Valuation
|
Metric
|
SYBX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.39 |
Price/Sales | 3.47 |
Price/Cash Flow | — |
Price/Earnings
SYBX
Financial Strength
|
Metric
|
SYBX
|
|---|---|
Quick Ratio | 2.34 |
Current Ratio | 2.45 |
Interest Coverage | −59,736.00 |
Quick Ratio
SYBX
Profitability
|
Metric
|
SYBX
|
|---|---|
Return on Assets (Normalized) | −60.96% |
Return on Equity (Normalized) | −88.77% |
Return on Invested Capital (Normalized) | −69.63% |
Return on Assets
SYBX
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Dwyzlrrrgh | Kmg | $557.8 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Sjkkdtqym | Bldmdq | $103.3 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Sfptgkj | Dfschx | $98.8 Bil | |
MRNA
| Moderna Inc | Pntkxvx | Lvvk | $38.8 Bil | |
ARGX
| argenx SE ADR | Mcbrmffh | Crlr | $21.3 Bil | |
BNTX
| BioNTech SE ADR | Npxlqrx | Dldr | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Dzptgrg | Hzysgkq | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Lbkbjtgp | Hfzvyx | $17.0 Bil | |
RPRX
| Royalty Pharma PLC Class A | Pprnkrdlk | Grsrkt | $12.4 Bil | |
INCY
| Incyte Corp | Vmzmdfj | Mcyrp | $11.9 Bil |